Distribution of type 2 biomarkers and association with severity, clinical characteristics and comorbidities in the BREATHE real-life asthma population.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
19
09
2022
accepted:
30
09
2022
entrez:
23
3
2023
pubmed:
24
3
2023
medline:
24
3
2023
Statut:
epublish
Résumé
Type 2 (T2) high asthma is recognised as a heterogenous entity consisting of several endotypes; however, the prevalence and distribution of the T2 biomarkers in the general asthma population, across asthma severity, and across compartments is largely unknown. The objective of the present study was to describe expression and overlaps of airway and systemic T2 biomarkers in a clinically representative asthma population. Patients with asthma from the real-life BREATHE cohort referred to a specialist centre were included and grouped according to T2 biomarkers: blood and sputum eosinophilia (≥0.3×10 Patients with mild-to-moderate asthma were younger (41 Severe asthma is more commonly associated with activation of several T2 pathways, indicating that treatments targeting severe asthma may need to act more broadly on T2 inflammatory pathways. Implementation of airway inflammometry in clinical care is of paramount importance, as the best treatable trait is otherwise is overlooked in a large proportion of patients irrespective of disease severity.
Sections du résumé
Background
UNASSIGNED
Type 2 (T2) high asthma is recognised as a heterogenous entity consisting of several endotypes; however, the prevalence and distribution of the T2 biomarkers in the general asthma population, across asthma severity, and across compartments is largely unknown. The objective of the present study was to describe expression and overlaps of airway and systemic T2 biomarkers in a clinically representative asthma population.
Methods
UNASSIGNED
Patients with asthma from the real-life BREATHE cohort referred to a specialist centre were included and grouped according to T2 biomarkers: blood and sputum eosinophilia (≥0.3×10
Results
UNASSIGNED
Patients with mild-to-moderate asthma were younger (41
Conclusion
UNASSIGNED
Severe asthma is more commonly associated with activation of several T2 pathways, indicating that treatments targeting severe asthma may need to act more broadly on T2 inflammatory pathways. Implementation of airway inflammometry in clinical care is of paramount importance, as the best treatable trait is otherwise is overlooked in a large proportion of patients irrespective of disease severity.
Identifiants
pubmed: 36949964
doi: 10.1183/23120541.00483-2022
pii: 00483-2022
pmc: PMC10026007
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflicts of interest: L. Frøssing, D.K. Klein, N. Obling, J.S. Erjefält and U. Bodtger report no conflicts of interest in relation to the current manuscript. M. Hvidtfeldt and C. Porsbjerg report unrestricted grants from Teva and AstraZeneca. G. Telg is employed by AstraZeneca Nordic.
Références
J Allergy Clin Immunol. 2007 Feb;119(2):405-13
pubmed: 17291857
Clin Exp Allergy. 2018 Aug;48(8):935-943
pubmed: 29575336
Curr Drug Targets Inflamm Allergy. 2005 Aug;4(4):471-9
pubmed: 16101524
N Engl J Med. 2014 Sep 25;371(13):1198-207
pubmed: 25199059
Chest. 2021 Sep;160(3):814-830
pubmed: 33887242
N Engl J Med. 2021 May 13;384(19):1800-1809
pubmed: 33979488
Thorax. 2004 Sep;59(9):757-60
pubmed: 15333851
Am J Respir Crit Care Med. 2012 Mar 15;185(6):612-9
pubmed: 22268133
Eur Respir J. 2014 Jul;44(1):97-108
pubmed: 24525441
J Allergy Clin Immunol. 2013 Nov;132(5):1086-1096.e5
pubmed: 23866823
Thorax. 2010 May;65(5):384-90
pubmed: 19996343
Eur Clin Respir J. 2020 Mar 17;7(1):1736934
pubmed: 32284828
Clin Transl Allergy. 2019 Aug 21;9:41
pubmed: 31452870
Respir Med. 2018 Jan;134:117-123
pubmed: 29413497
Respirology. 2022 Aug;27(8):573-577
pubmed: 35591794
Am J Respir Crit Care Med. 2011 Nov 15;184(10):1125-32
pubmed: 21852542
Clin Transl Allergy. 2018 May 04;8:13
pubmed: 29755730
Respiration. 2012;83(1):36-44
pubmed: 21912093
Clin Exp Allergy. 2008 Jun;38(6):936-46
pubmed: 18384429
N Engl J Med. 2018 Jun 28;378(26):2486-2496
pubmed: 29782217
Eur Respir J. 2017 May 1;49(5):
pubmed: 28461308
Chron Respir Dis. 2015 Aug;12(3):197-203
pubmed: 25761367
J Allergy Clin Immunol. 2003 Nov;112(5):883-92
pubmed: 14610474
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1267-1275
pubmed: 33039645
Respirology. 2006 Jan;11(1):54-61
pubmed: 16423202
N Engl J Med. 2018 Jun 28;378(26):2475-2485
pubmed: 29782224
Respir Med. 2014 Jun;108(6):830-41
pubmed: 24636813
Am J Respir Crit Care Med. 2011 Sep 1;184(5):602-15
pubmed: 21885636
Eur Respir J. 2020 Nov 12;56(5):
pubmed: 32586879
Am J Respir Crit Care Med. 2013 Apr 15;187(8):804-11
pubmed: 23471469
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Eur Respir J. 2014 Feb;43(2):343-73
pubmed: 24337046
J Allergy Clin Immunol Pract. 2021 Mar;9(3):1224-1231.e9
pubmed: 33130147
J Allergy Clin Immunol. 2016 Nov;138(5):1301-1308.e2
pubmed: 27113848
Nat Immunol. 2015 Jan;16(1):45-56
pubmed: 25521684
J Allergy Clin Immunol. 2010 Nov;126(5):952-8
pubmed: 20934208
Lancet. 2016 Oct 29;388(10056):2115-2127
pubmed: 27609408
J Allergy Clin Immunol Pract. 2018 Jan - Feb;6(1):274-276.e2
pubmed: 28803182
N Engl J Med. 2009 Mar 5;360(10):973-84
pubmed: 19264686
Clin Exp Allergy. 2022 Jan;52(1):59-69
pubmed: 34142396
J Allergy Clin Immunol. 2017 Jun;139(6):1797-1807
pubmed: 27773852
N Engl J Med. 2017 Sep 7;377(10):936-946
pubmed: 28877011
N Engl J Med. 2019 May 23;380(21):2009-2019
pubmed: 31112384
Lancet Respir Med. 2021 Nov;9(11):1299-1312
pubmed: 34256031
Lancet Respir Med. 2015 Apr;3(4):290-300
pubmed: 25801413
Curr Opin Pulm Med. 2019 Jan;25(1):79-86
pubmed: 30422896
J Allergy Clin Immunol Pract. 2020 Feb;8(2):442-450
pubmed: 32037108
Am J Respir Crit Care Med. 2019 Nov 15;200(10):1308-1312
pubmed: 31298922
J Allergy Clin Immunol. 2013 Oct;132(4):821-7.e1-5
pubmed: 23890753
Cochrane Database Syst Rev. 2014 Jan 13;(1):CD003559
pubmed: 24414989
ERJ Open Res. 2020 Mar 09;6(1):
pubmed: 32166086